MA46430B1 - Thérapie combinée d'agonistes de cnp à libération contrôlée - Google Patents

Thérapie combinée d'agonistes de cnp à libération contrôlée

Info

Publication number
MA46430B1
MA46430B1 MA46430A MA46430A MA46430B1 MA 46430 B1 MA46430 B1 MA 46430B1 MA 46430 A MA46430 A MA 46430A MA 46430 A MA46430 A MA 46430A MA 46430 B1 MA46430 B1 MA 46430B1
Authority
MA
Morocco
Prior art keywords
controlled
combination therapy
treatment
release cnp
growth
Prior art date
Application number
MA46430A
Other languages
English (en)
Other versions
MA46430A (fr
Inventor
Kennett Sprogøe
Lars Holten-Andersen
Breinholt Vibeke Miller
Original Assignee
Ascendis Pharma Growth Disorders As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57047055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA46430(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ascendis Pharma Growth Disorders As filed Critical Ascendis Pharma Growth Disorders As
Publication of MA46430A publication Critical patent/MA46430A/fr
Publication of MA46430B1 publication Critical patent/MA46430B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur une combinaison d'un agoniste du cnp et d'au moins un autre fragment, ou médicament biologiquement actif, destiné à être utilisé dans un procédé de traitement, ou dans la prévention d'un troubles qui bénéficient de la stimulation de la croissance. Les compositions pharmaceutiques comprennent, au moins, un agoniste du cnp, de préférence un agoniste du cnp à libération contrôlée. La composition pharmaceutique comprend, au moins, une autre fraction, ou un médicament biologiquement actif, pour utiliser ces compositions pharmaceutiques en tant que médicament, pour être utilisé dans le traitement de troubles qui bénéficient de la stimulation de la croissance, et dans des procédés de prévention, ou de traitement d'un patient ayant un trouble qui bénéficie de la stimulation de la croissance.
MA46430A 2016-09-29 2017-09-28 Thérapie combinée d'agonistes de cnp à libération contrôlée MA46430B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16191456 2016-09-29
PCT/EP2017/074596 WO2018060314A1 (fr) 2016-09-29 2017-09-28 Thérapie combinée d'agonistes de cnp à libération contrôlée

Publications (2)

Publication Number Publication Date
MA46430A MA46430A (fr) 2019-08-07
MA46430B1 true MA46430B1 (fr) 2023-07-31

Family

ID=57047055

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46430A MA46430B1 (fr) 2016-09-29 2017-09-28 Thérapie combinée d'agonistes de cnp à libération contrôlée

Country Status (26)

Country Link
US (2) US11564974B2 (fr)
EP (2) EP4223309A1 (fr)
JP (1) JP7189133B2 (fr)
KR (2) KR102531327B1 (fr)
CN (1) CN109843295B (fr)
AU (2) AU2017336253B2 (fr)
BR (1) BR112019005351A2 (fr)
CA (1) CA3037448A1 (fr)
DK (1) DK3518930T3 (fr)
ES (1) ES2943013T3 (fr)
FI (1) FI3518930T3 (fr)
HR (1) HRP20230385T1 (fr)
HU (1) HUE062117T2 (fr)
IL (3) IL305975A (fr)
LT (1) LT3518930T (fr)
MA (1) MA46430B1 (fr)
MX (1) MX2019003173A (fr)
NZ (1) NZ751746A (fr)
PL (1) PL3518930T3 (fr)
PT (1) PT3518930T (fr)
RS (1) RS64203B1 (fr)
RU (1) RU2768747C2 (fr)
SG (2) SG10202111952PA (fr)
SI (1) SI3518930T1 (fr)
WO (1) WO2018060314A1 (fr)
ZA (1) ZA201901810B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017118707A1 (fr) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Agonistes de cnp à libération contrôlée présentant des effets secondaires réduits
HRP20221339T1 (hr) 2016-01-08 2023-01-06 Ascendis Pharma Growth Disorders A/S Cnp predlijekovi s učvršćenjem nosača na cikličkom dijelu peptida
EP3400021A1 (fr) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Agonistes de cnp à libération contrôlée présentant une faible liaison à npr-c
MX2018008061A (es) * 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
AU2017205693B2 (en) 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
US20200276276A1 (en) * 2016-03-01 2020-09-03 Ascendis Pharma Bone Diseases A/S PTH Prodrugs
FI3518960T3 (fi) 2016-09-29 2023-10-04 Ascendis Pharma Bone Diseases As Annostusohjelma kontrolloidusti vapautuvalle PTH-yhdisteelle
CA3037448A1 (fr) 2016-09-29 2018-04-05 Ascendis Pharma Growth Disorders A/S Therapie combinee d'agonistes de cnp a liberation controlee
MX2019003182A (es) 2016-09-29 2019-08-05 Ascendis Pharma Bone Diseases As Compuestos de hormona paratiroidea con bajas relaciones pico - valle.
WO2024104922A1 (fr) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Procédé d'amélioration de la fonction musculaire squelettique

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0892789T2 (sl) 1996-04-12 2010-03-31 Warner Lambert Co Ireverzibilni inhibitorji tirozin kinaz
AU8689298A (en) 1997-08-05 1999-03-01 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
CA2345414A1 (fr) 1998-09-28 2000-04-06 Santen Pharmaceutical Co., Ltd. Gouttes ophtalmologiques contenant des peptides natriuretiques comme principes actifs afin de promouvoir la secretion lacrymale ou pour traiter la keratoconjonctivite
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP4252746B2 (ja) * 2001-10-05 2009-04-08 一和 中尾 軟骨無形成症治療剤
ES2516041T3 (es) 2001-10-10 2014-10-30 Ratiopharm Gmbh Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH)
US7054679B2 (en) 2001-10-31 2006-05-30 Robert Hirsh Non-invasive method and device to monitor cardiac parameters
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
BR0316560A (pt) * 2002-11-26 2005-10-04 Nobex Corp Conjugado de composto natriurético, formulação farmacêutica, método de tratar uma condição, método de preparação do conjugado de composto natriurético, conjugado de peptìdeo pró-polinatriurético modificado, análogo de peptìdeo natriurético, análogo de hbnp, composto, e, método de preparar um composto
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
WO2004089280A2 (fr) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Medicaments pegyles reversibles
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
US8377917B2 (en) 2004-03-23 2013-02-19 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CU23556A1 (es) 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
WO2008031045A2 (fr) 2006-09-08 2008-03-13 Mayo Foundation For Medical Education And Research Polypeptides aquarétiques et natriurétiques dépourvus d'activité vasodilatatoire
JP2010503707A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー
AR063621A1 (es) 2006-11-09 2009-02-04 Alcon Res Ltd Matriz polimerica insoluble en agua para la administracion de farmacos
KR20080098216A (ko) * 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
CA2693616A1 (fr) 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Systeme d'administration de medicament polymerique contenant un groupement aromatique multi-substitue
US8377884B2 (en) 2007-11-21 2013-02-19 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptides
MX2010008024A (es) 2008-02-01 2010-12-21 Ascendis Pharma As Profarmaco que comprende un enlazador que se puede separar por si mismo.
WO2009143412A2 (fr) 2008-05-23 2009-11-26 Enzon Pharmaceuticals, Inc. Systèmes polymères contenant un lieur disulfure intracellulaire libérable pour la délivrance d’oligonucléotides
WO2009156481A1 (fr) 2008-06-25 2009-12-30 Ascendis Pharma As Bnp pégylé
WO2010033216A1 (fr) * 2008-09-19 2010-03-25 Nektar Therapeutics Conjugués polymères de peptides de nesiritide
DK2393828T3 (en) 2009-02-03 2017-01-23 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
PE20120792A1 (es) 2009-05-20 2012-07-27 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
EP2459227B1 (fr) 2009-07-31 2021-03-17 Ascendis Pharma A/S Promédicaments contenant une amine aromatique liée à un support par liaison amide
WO2011012715A1 (fr) 2009-07-31 2011-02-03 Ascendis Pharma As Hydrogels insolubles dans l’eau à base de polyéthylène glycol biodégradable
WO2011031441A1 (fr) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Thérapie avec une molécule chimérique et un agent pro-apoptotique
WO2011075471A2 (fr) 2009-12-18 2011-06-23 Alcon Research, Ltd. Nouveaux agonistes du npr-b et méthodes d'utilisation pour le traitement des troubles médiés par le peptide natriurétique de type c
WO2011082368A2 (fr) 2009-12-31 2011-07-07 Enzon Pharmaceuticals, Inc Conjugués polymères de composés contenant un groupement amine aromatique comprenant un lieur d'urée libérable
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
WO2011123813A2 (fr) 2010-04-02 2011-10-06 Amunix Operating Inc. Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
EP2566335B1 (fr) 2010-05-05 2016-06-29 Prolynx Llc Libération contrôlée de principes actifs à partir de conjugués macromoléculaires
US8946405B2 (en) 2010-05-05 2015-02-03 Prolynx Llc Controlled release from solid supports
EP2571510B1 (fr) 2010-05-21 2018-08-08 XL-protein GmbH Polypeptides de bobine aléatoires en proline/alanine biosynthétique
WO2012002047A1 (fr) 2010-06-30 2012-01-05 Ｎｅｃソフト株式会社 Procédé de détermination d'attributs, dispositif de détermination d'attributs, programme, support d'enregistrement et système de détermination d'attributs
EP3643306A3 (fr) 2011-08-12 2020-08-26 Ascendis Pharma A/S Promédicaments liés à un support dotés de liaisons ester carboxylique réversibles
CN103857413A (zh) 2011-08-12 2014-06-11 阿森迪斯药物股份有限公司 载体连接的曲罗尼尔前药
CA2843503C (fr) 2011-08-12 2020-12-22 Ulrich Hersel Promedicaments lies a des excipients polymeriques hyperbranches
WO2013024047A1 (fr) 2011-08-12 2013-02-21 Ascendis Pharma A/S Promédicaments liés à des excipients hydrosolubles de forte charge
AU2012296951B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
WO2013036857A1 (fr) 2011-09-07 2013-03-14 Prolynx Llc Coupleurs au sulfone
US20150087688A1 (en) 2012-04-25 2015-03-26 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
TWI578995B (zh) * 2012-04-25 2017-04-21 第一三共股份有限公司 利尿鈉肽受體npr-b促效劑之用途
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EP2906617B1 (fr) 2012-10-11 2018-03-14 Ascendis Pharma A/S Promédicaments à base d'hydrogel
EP2908845A1 (fr) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Acides aminés acylés par un acide gras pour l'administration d'hormone de croissance
JP6536871B2 (ja) 2013-12-02 2019-07-03 国立大学法人京都大学 Ｆｇｆｒ３病の予防および治療剤ならびにそのスクリーニング方法
JPWO2015129812A1 (ja) 2014-02-27 2017-03-30 第一三共株式会社 ステロイド剤投与で誘発される成長障害に対する医薬
KR102608645B1 (ko) 2014-11-18 2023-12-01 아센디스 파마 엔도크리놀로지 디비전 에이/에스 신규한 중합체성 hGH 프로드러그
US20170368189A1 (en) 2015-01-09 2017-12-28 Ascendis Pharma Growth Disorders A/S Cnp prodrugs
US11202819B2 (en) 2015-12-08 2021-12-21 Biomarin Pharmaceutical Inc. Use of C-type natriuretic peptide variants to treat osteoarthritis
HRP20221339T1 (hr) 2016-01-08 2023-01-06 Ascendis Pharma Growth Disorders A/S Cnp predlijekovi s učvršćenjem nosača na cikličkom dijelu peptida
IL293979B1 (en) 2016-01-08 2024-04-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with increased NEP stability
AU2017205693B2 (en) 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
EP3400021A1 (fr) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Agonistes de cnp à libération contrôlée présentant une faible liaison à npr-c
MX2018008061A (es) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
WO2017118707A1 (fr) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Agonistes de cnp à libération contrôlée présentant des effets secondaires réduits
US20200276276A1 (en) 2016-03-01 2020-09-03 Ascendis Pharma Bone Diseases A/S PTH Prodrugs
CA3037448A1 (fr) 2016-09-29 2018-04-05 Ascendis Pharma Growth Disorders A/S Therapie combinee d'agonistes de cnp a liberation controlee
WO2020037285A1 (fr) 2018-08-16 2020-02-20 Beyondspring Pharmaceuticals, Inc. Méthode et composition pour stimuler une réponse immunitaire
US20220118053A1 (en) 2019-02-11 2022-04-21 Ascendis Pharma Growth Disorders A/S Dry Pharmaceutical Formulations of CNP Conjugates

Also Published As

Publication number Publication date
RS64203B1 (sr) 2023-06-30
KR20230066147A (ko) 2023-05-12
DK3518930T3 (da) 2023-05-01
AU2017336253B2 (en) 2023-02-23
FI3518930T3 (fi) 2023-05-04
IL265592A (en) 2019-05-30
IL290054B2 (en) 2024-03-01
MA46430A (fr) 2019-08-07
US20200276270A1 (en) 2020-09-03
CN109843295A (zh) 2019-06-04
HRP20230385T1 (hr) 2023-06-23
IL305975A (en) 2023-11-01
RU2019112897A (ru) 2020-10-30
EP4223309A1 (fr) 2023-08-09
CA3037448A1 (fr) 2018-04-05
US20230302091A1 (en) 2023-09-28
IL290054B1 (en) 2023-11-01
KR102531327B1 (ko) 2023-05-11
IL265592B (en) 2022-02-01
HUE062117T2 (hu) 2023-09-28
BR112019005351A2 (pt) 2019-06-11
SI3518930T1 (sl) 2023-06-30
SG11201901534VA (en) 2019-03-28
AU2023201709A1 (en) 2023-05-25
ES2943013T3 (es) 2023-06-08
CN109843295B (zh) 2022-04-05
LT3518930T (lt) 2023-05-10
JP2019535647A (ja) 2019-12-12
MX2019003173A (es) 2019-07-08
RU2019112897A3 (fr) 2021-01-18
SG10202111952PA (en) 2021-12-30
ZA201901810B (en) 2019-12-18
NZ751746A (en) 2023-06-30
WO2018060314A1 (fr) 2018-04-05
JP7189133B2 (ja) 2022-12-13
EP3518930B1 (fr) 2023-03-08
PT3518930T (pt) 2023-04-28
KR20190062498A (ko) 2019-06-05
PL3518930T3 (pl) 2023-09-11
RU2768747C2 (ru) 2022-03-24
AU2017336253A1 (en) 2019-03-21
IL290054A (en) 2022-03-01
US11564974B2 (en) 2023-01-31
EP3518930A1 (fr) 2019-08-07

Similar Documents

Publication Publication Date Title
MA46430B1 (fr) Thérapie combinée d'agonistes de cnp à libération contrôlée
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA41932B1 (fr) Méthodes de traitement ou de prévention de migraines
MA32056B1 (fr) Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MA40290A1 (fr) Agents immunorégulateurs
MA40769A (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MX2022001874A (es) Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos.
MA42811A (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA39443A1 (fr) Nouvelle formulation de méloxicam
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA38576A1 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
MA40863A (fr) Thiazoles en tant que modulateurs de roryt
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
MA29453B1 (fr) Associations synergiques de medicaments anti-inflammatoires non steroidiens avec des ligands d'alpha-2-delta
BR112021018262A2 (pt) Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
BR112016026470A8 (pt) composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
MA34106B1 (fr) Combinaison de composés organiques
BR112019004520A2 (pt) composto, medicamento, métodos para inibição de um receptor toll-like 4 e para prevenção ou tratamento de uma doença, e, uso do composto.
BR112022007348A2 (pt) Métodos para tratar condições relacionadas ao receptor s1p1
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical